- Home
- CRBU vs KYTX Comparison
CRBU vs KYTX Comparison
Compare CRBU & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- KYTX
- Stock Information
- Founded
- CRBU 2011
- KYTX 2018
- Country
- CRBU United States
- KYTX United States
- Employees
- CRBU N/A
- KYTX N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- KYTX
- Sector
- CRBU Health Care
- KYTX
- Exchange
- CRBU Nasdaq
- KYTX NYSE
- Market Cap
- CRBU 93.0M
- KYTX 92.1M
- IPO Year
- CRBU 2021
- KYTX 2024
- Fundamental
- Price
- CRBU $1.02
- KYTX $2.64
- Analyst Decision
- CRBU Strong Buy
- KYTX Strong Buy
- Analyst Count
- CRBU 4
- KYTX 5
- Target Price
- CRBU $8.50
- KYTX $19.00
- AVG Volume (30 Days)
- CRBU 943.1K
- KYTX 382.4K
- Earning Date
- CRBU 05-08-2025
- KYTX 05-13-2025
- Dividend Yield
- CRBU N/A
- KYTX N/A
- EPS Growth
- CRBU N/A
- KYTX N/A
- EPS
- CRBU N/A
- KYTX N/A
- Revenue
- CRBU $9,918,000.00
- KYTX N/A
- Revenue This Year
- CRBU N/A
- KYTX N/A
- Revenue Next Year
- CRBU $161.81
- KYTX N/A
- P/E Ratio
- CRBU N/A
- KYTX N/A
- Revenue Growth
- CRBU N/A
- KYTX N/A
- 52 Week Low
- CRBU $0.66
- KYTX $1.78
- 52 Week High
- CRBU $3.00
- KYTX $16.64
- Technical
- Relative Strength Index (RSI)
- CRBU 57.50
- KYTX 57.79
- Support Level
- CRBU $0.98
- KYTX $2.47
- Resistance Level
- CRBU $1.21
- KYTX $2.82
- Average True Range (ATR)
- CRBU 0.10
- KYTX 0.23
- MACD
- CRBU 0.02
- KYTX 0.04
- Stochastic Oscillator
- CRBU 68.23
- KYTX 68.42
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.